Table 2. Multivariable adjusted odds ratios (OR) of colorectal and colon cancer by median of plasma analyte level, HPFS and NHS combined.
| Colorectal Cancer | Colon Cancer | |||
| Plasma Marker | Low* | High* | Low | High |
| IGF-1 | ||||
| Cases/controls | 220/497 | 279/495 | 156/360 | 210/367 |
| OR (95% CI)$ | 1.00 | 1.37 (1.05 to 1.78) | 1.00 | 1.52 (1.11 to 2.07) |
| IGFBP3 | ||||
| Cases/controls | 230/496 | 269/496 | 171/362 | 195/365 |
| OR (95% CI) | 1.00 | 0.96 (0.74 to 1.26) | 1.00 | 0.91 (0.68 to 1.25) |
| Molar IGF-1/IGFBP3 Ratio | ||||
| Cases/controls | 219/497 | 280/495 | 159/353 | 207/374 |
| OR (95% CI) | 1.00 | 1.36 (1.08 to 1.73) | 1.00 | 1.35 (1.02 to 1.79) |
| C-Peptide † | ||||
| Cases/controls | 197/455 | 277/460 | 140/337 | 211/339 |
| OR (95% CI) | 1.00 | 1.37 (1.05 to 1.78) | 1.00 | 1.58 (1.16 to 2.16) |
| Vitamin D | ||||
| Cases/controls | 302/498 | 197/494 | 224/354 | 142/373 |
| OR (95% CI) | 1.00 | 0.67 (0.53 to 0.86) | 1.00 | 0.62(0.47 to 0.83) |
*Low: below median level; high: equal or above median level.
Median vitamin D levels (controls): HPFS: 29.6 ng/mL; NHS: laboratory batch 1: 23.8 ng/mL; laboratory batch 2: 29.7 ng/mL, laboratory batch 3: 25.5 ng/mL.
$Multivariable adjusted for matching factors (age, year and month of blood donation), body mass index (kg/m2, continuous), packyears of smoking (continuous), physical activity (MET-hr week, continuous), intake of alcohol, methionine, folate, retinol, red and processed meat, calcium (all intake covariates as continuous variables), family historyof colorectal cancer (yes vs. no), sex, fasting status (0–2, 3–4, 5–8, ≥9 hours since last meal), aspirin use (<2 tablets/week, past, ≥2 tablets/week); models for IGF-1 were adjusted for IGF-BP3 (in tertiles) and vice versa.
Models for C-Peptide only included participants without self-reported diabetes mellitus.